Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Buffett’s Berkshire Hathaway Doubles Shares of Teva
Error: Contact form not found.
by JNS.org
Israeli Prime Minister Ehud Olmert (left) shakes hands with investor Warren Buffett during a meeting at the Prime Minister’s Office in Jerusalem on Sept. 18, 2006. Photo: Orel Cohen/Flash90.
JNS.org – Investment giant Warren Buffett’s Berkshire Hathaway doubled its stake in Israel’s Teva Pharmaceutical Industries on Tuesday.
It owned 18.8 million shares at the end of 2017—a 1.8 percent stake worth $358 million.
Berkshire published its holdings as of March 31 after the close of trading on Wall Street on Tuesday, showing it now owns 40.5 million shares—a 3.45 percent stake in Teva. The announcement shot Teva’s share price up by nearly 5 percent in after-hours trading.
The price dipped slightly when Buffett announced that he had not personally picked the stock.
The news is a boon for Teva, which has suffered serious decline in recent years. Its 2016 acquisition of generic drug-maker Allergan left the company in serious debt just as Teva’s star treatment for multiple sclerosis, Copaxone, was eligible for generic competition.
The downturn led to the resignation of multiple upper-echelon executives, including Teva’s CEO, and the plummeting of Teva’s New York-listed shares by 50 percent.
Teva has been making a turnaround in 2018, with revenues higher than anticipated.
